Journal of Clinical Oncology
Articles in this Issue
Efficacy and safety of recombinant human thrombopoietin (rhTPO) for thrombocytopenia induced by combinatorial interventional, targeted, and immunotherapy in hepatocellular carcinoma (SYNERGY-TPOACT): A retrospective cohort study.
e16250 Background: Combination regimens integrating interventional therapies (TACE/HAIC) with tyrosine kinase inhibitors (...
Phase II trial of SYS6010, an EGFR antibody-drug conjugate (ADC) in patients with advanced esophageal squamous cell carcinoma (ESCC).
4047 Background: SYS6010 is an EGFR- ADC composed of an EGFR-specific antibody, a cleavable linker, and the topoisomerase...
Dose optimization in FDA oncology drug approvals: Factors associated with observing exposure-efficacy relationships.
e15127 Background: Exposure–response analysis has been recognized as a fundamental component in dose selection, optimizati...
Fruquintinib plus FOLFIRI or mFOLFOX6 as second-line therapy for patients with <i>RAS</i> -mutant metastatic colorectal cancer (mCRC): A phase II, multicenter, open-label study.
3528 Background: Nearly half of metastatic colorectal cancer (mCRC) patients harbor RAS mutations, and the standard second...
Impact of dedicated care coordination on access to multidimensional support services in young-onset colorectal cancer: A pragmatic trial.
11008 Background: The incidence of young-onset colorectal cancer (YOCRC) is increasing, and affected patients experience d...
Association of skin cancer with Bruton tyrosine kinase inhibitors: A FAERS analysis.
e21551 Background: Bruton tyrosine kinase inhibitors (BTKis)—including Ibrutinib, Acalabrutinib, Zanubrutinib, and Pirtobr...
Beyond TMB: Characterizing tumor-intrinsic genomic architectures of immune resistance.
2586 Background: Immune checkpoint inhibitors (ICI) are increasingly selected based on tumor mutational burden (TMB); howe...
Efficacy of venetoclax-based therapy in t(11;14)–positive relapsed/refractory multiple myeloma: A systematic review and meta-analysis.
e19570 Background: Translocation between chromosomes 11 and 14 [t(11;14)] is one of the most common primary cytogenetic ab...
<i>MTAP</i> deletions and co-mutational landscape from whole genome sequencing in primary CNS tumors.
3117 Background: Biallelic deletions of the MTAP (methylthioadenosine phosphorylas...
HER2 expression in squamous cell carcinoma of the vulva: A systematic review and meta-analysis.
e17653 Background: Vulvar cancer is a rare gynecologic malignancy comprising 1–3% of all cases. No established standard ex...
Adjuvant oxaliplatin plus S-1 versus docetaxel plus S-1 for stage III gastric cancer after D2 gastrectomy (DRAGON-Adjuvant): A multicenter, open-label, phase 3, randomized, non-inferiority study.
TPS4249 Background: Adjuvant therapy is the standard treatment for stage II-III gastric cancer patients after radical D2 g...
Serum VEGF-A concentrations as a predictive biomarker of immunotherapy response in refractory metastatic colorectal cancer (mCRC): An exploratory analysis of CCTG CO.26.
3547 Background: Benefits of immune checkpoint inhibitors (ICIs) in unselected proficient mismatch repair (pMMR) mCRC rema...
Targeted bronchial washing fluid–based sequencing for detection of actionable genomic alterations in early-stage non–small cell lung cancer: A comparative analysis with plasma and surgical tissue.
e20056 Background: In early-stage non–small cell lung cancer (NSCLC), plasma-based liquid biopsy has limited sensitivity d...
Patterns in place of death amongst Black women with breast cancer: A retrospective study.
e13741 Background: Breast cancer remains a leading cause of cancer-related mortality amongst Black women, who experience d...
Updated two-year overall survival and toxicity outcomes of BCMA CAR-T therapy compared with teclistamab in multiple myeloma.
7527 Background: B-cell maturation antigen (BCMA) targeted chimeric antigen receptor T-cell therapy (CAR-T) and bispecific...
Predictive value of ctDNA-based MRD combined with PET-CT and gastroscopy for treatment efficacy in locally advanced esophageal squamous cell carcinoma: A phase II exploratory clinical trial.
e16119 Background: Based on the SANO trial establishing active surveillance non-inferiority after clinical complete respon...
Clinical outcomes of patients with PI3K pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study.
3150 Background: The phosphatidylinositol 3-kinase (PI3K) pathway regulates cell growth, metabolism, and survival and is i...
Sequencing trastuzumab deruxtecan and sacituzumab govitecan in metastatic breast cancer: A systematic review and meta-analysis.
e13074 Background: Antibody–drug conjugates (ADCs) have significantly improved outcomes in metastatic breast cancer (mBC),...
Impact of fertility concerns on endocrine therapy.
631 Background: Adolescent and young adult (AYA) women with breast cancer who have not completed their desired childbearin...
Spectrum of germline pathogenic and novel BRCA1 and BRCA2 gene mutations in a cohort of 1780 breast and ovarian carcinoma patients from east India.
10614 Background: Advances in our understanding of the molecular basis of cancer have pushed us in a new era of personaliz...
Psychosocial interventions in the care of individuals with hereditary cancer risk: A scoping review.
e22660 Background: Individuals with hereditary cancer predisposition syndromes experience significant psychological distre...
Leveraging spatial proteomics to identify epithelial cell subtypes driving poor prognosis in prostate cancer.
5126 Background: Epithelial cell features, such as morphology and cellular organization within the tumor architecture (e.g...
Quantitative results from PSMAtrack: A prospective study evaluating changes in PSMA-PET during initial systemic therapy for metastatic hormone-sensitive prostate cancer (mHSPC).
5102 Background: PSA <0.2 ng/mL after 6 months (m) of therapy with androgen deprivation therapy (ADT) and an androgen r...
Clinical validity of ultrasensitive single-digit parts per million ctDNA detection in non–small cell lung cancer.
8017 Background: Circulating tumor DNA (ctDNA) is a promising biomarker for detecting molecular residual disease (MRD) and...
Progress report of a phase 2 study of BPM31510 (a lipid nano dispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy.
TPS2101 Background: BPM31510 is an investigational, drug-lipid conjugate nanodispersion. Preclinical studies demonstrate t...